Drugs / Autologous DC-CIK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07260058 | Dec 2025 → Jun 2027 expected | breast cancer, colorectal cancer, liver cancer, lung cancer | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous DC-CIK Cells | “1. Autologous DC-CIK Cells：Dendritic Cells (DC) and Cytokine-Induced Killer (CIK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs).” NCT07260058 ↗ |
| Modality | Cell therapy | “autologous immune cell therapy” NCT07260058 ↗ |
| Route | Subcutaneous | “are administered via subcutaneous injection” NCT07260058 ↗ |